Treatment of refractory metastatic breast cancer with 5-fluorouracil and levofolinic acid as 48 hours continuous venous infusion

被引:0
|
作者
Gebbia, V
Mauceri, G
Testa, A
Tirrito, M
Varvara, F
Cucchiara, A
Borsellino, N
Girlando, A
Ferrara, M
Caruso, F
机构
[1] Ctr Catanese Oncol, Div Med Oncol, I-95100 Catania, Italy
[2] Clin Macchiarella, Div Oncol, Palermo, Italy
[3] Clin Torina, Serv Oncol, Palermo, Italy
[4] Ctr Catanese Oncol, Div Radiotherapy, Catania, Italy
[5] Ctr Catanese Oncol, Div Surg Oncol, I-95100 Catania, Italy
关键词
breast cancer; metastases; 5-fluorouracil; levofolinic acid; vinorelbine;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Twenty-four consecutive patients with metastatic breast carcirioma (MBC) refractory to first line chemotherapy 2 were treated with high-dose folinic acid (FA) 100 mg/m(2) diluted in 250 cc of normal saline as 2 2 hour infusion followed by 5-fluorouracil (5FU) 400 mg/m(2) bolus then 5FU 600 mg/m(2) as continuous infusion for 22 hours. This therapy was repeated for 2 consecutive days. Chemotherapy was repeated every 15 days. All enrolled patients were evaluable for objective response. A complete response was achieved in 1 patient (4%) and a partial response in 6 cases (25%) for an overall response rate of 29% (confidence limits 18%-39%). The median duration of objective responses was 8.4+ months (range 3.0+/12.8). Six patients showed no change (25%) with a median duration of 4.0 months 11 patients progressed (46%). A subjective improvemernt in tumor-related symptoms was reported by all responding patients and in 3 patients with no change. Most patients (7/10) with symptomatic bone lesions had a subjective improvement with reduction in analgesic drugs consumption. Objective responses were observed at all sites of disease. In fact, responses were seen in the skin liver lung bore and rodal metastases. The median overall survival was 13.0+ months (range 4.0/16.2+). Over a total of 160 cycles (a mean of 6.6 cycles/patient) grade 1-2 leukopenia was seen in 9 patients (37%) grade 1 thrombocytoperia in 4 patients (17%) and grade 1 anemia in only 2 cases (8%). Grade 3-4 leukopenia or thrombocytopenia were not seen. Phlebitis at the injection vein occurred in 3/10 patients (30%) which refuded to implant a central line. In patients with a central line or a port-a-cath no cases of vascula toxicity were seen. Gastrointestinal toxicity was very mild with 9 patients (37%) suffering from grade 1- 2 nausea/vomiting 6 patients (25%) complaining of grade 1-2 diarrhea and 6 patients with grade 1-2 stomatitis. Hand-foot syndrome was observed in only 1 patient. No cases of grade 3-4 gastrointestinal toxicities have been, observed No cases of cardiotoxicity and/or neurotoxicity were recorded The combination of high-dose FA and 5FU given as 48 hour continuous venous infusion every 2 weeks is active, at least in. terms of objective response rate and tumor related symptoms palliation against anthracycline-refractory MBC These results compare favorably with bolus administration of FA and 5FU or other salvage regimens.
引用
收藏
页码:2289 / 2292
页数:4
相关论文
共 50 条
  • [31] Phase II study of recombinant alpha-interferon (rIFN alpha) and continuous-infusion 5-fluorouracil in metastatic breast cancer
    Walters, RS
    Theriault, RL
    Booser, DJ
    Esparza, L
    Hortobagyi, GN
    JOURNAL OF IMMUNOTHERAPY, 1995, 18 (03): : 185 - 187
  • [32] Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer
    O'Byrne, KJ
    Koukourakis, MI
    Saunders, MP
    Salisbury, AJ
    Isaacs, R
    Varcoe, S
    Taylor, M
    Ganesan, TS
    Harris, AL
    Talbot, DC
    BRITISH JOURNAL OF CANCER, 1998, 77 (11) : 1950 - 1956
  • [33] Vinorelbine and infusional 5-fluorouracil in anthracycline and taxane pre-treated metastatic breast cancer
    Stuart, N. S. A.
    McIllmurray, M. B.
    Bishop, J. L.
    Johnston, S. R. D.
    Price, C. G. A.
    O'Reilly, S. M.
    Joffe, J. K.
    Neave, F.
    Whipp, E. C.
    CLINICAL ONCOLOGY, 2008, 20 (02) : 152 - 156
  • [34] Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer
    Correale, P.
    Montagnani, F.
    Miano, S.
    Sciandivasci, A.
    Pascucci, A.
    Petrioli, R.
    Testi, W.
    Tanzini, G.
    Francini, G.
    JOURNAL OF CHEMOTHERAPY, 2008, 20 (01) : 119 - 125
  • [35] Continuous-infusion high-dose leucovorin with 5-fluorouracil and cisplatin for relapsed metastatic breast cancer: A phase II study
    Booser, DJ
    Walters, RS
    Holmes, FA
    Hortobagyi, GN
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (01): : 40 - 41
  • [36] Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study
    Humphreys, A
    Dent, J
    Rodwell, S
    Crawford, SM
    Joffe, JK
    Bradley, C
    Dodwell, D
    Perren, TJ
    BRITISH JOURNAL OF CANCER, 2004, 90 (11) : 2131 - 2134
  • [37] Treatment with a nonanthracycline regimen in advanced breast cancer - Vinorelbine, cyclophosphamide, and 5-fluorouracil with folinic acid
    Turpin, F
    Lluch, A
    Closen, MH
    Gruia, G
    Llombart, A
    Fernandez, R
    Delgado, FM
    Biville, F
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1999, 22 (02): : 196 - 198
  • [38] Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer
    Maindrault-Goebel, F
    de Gramont, A
    Louvet, C
    André, T
    Carola, E
    Gilles, V
    Lotz, JP
    Tournigand, C
    Mabro, M
    Molitor, JL
    Artru, P
    Izrael, V
    Krulik, M
    ANNALS OF ONCOLOGY, 2000, 11 (11) : 1477 - 1483
  • [39] A PHASE-II STUDY OF CISPLATINUM AND CONTINUOUS INFUSION 5-FLUOROURACIL FOR METASTATIC MELANOMA
    OLVER, IN
    BISHOP, JF
    GREEN, M
    ZIMET, A
    LAIDLAW, C
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1992, 15 (06): : 503 - 505
  • [40] ACTIVITY OF CONTINUOUS-INFUSION 5-FLUOROURACIL IN PATIENTS WITH ADVANCED COLORECTAL-CANCER CLINICALLY RESISTANT TO BOLUS 5-FLUOROURACIL
    MORI, A
    BERTOGLIO, S
    GUGLIELMI, A
    ASCHELE, C
    BOLLI, E
    TIXI, L
    ROSSO, R
    SOBRERO, A
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 33 (02) : 179 - 180